RxDoctor Payments Data

Barry Wein, MD

Family Medicine · Richmond, VANPI 1992776462

Payments from drug & device makers

$2,236in general payments, 2019–2025

Across 119 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$474
  • Lilly USA, LLC$289
  • AbbVie$262
  • Amgen$261
  • Pfizer$193
  • Novartis$135
  • plus $621 from 16 others

What the payments were for

  • Food & beverage$2,19398%
  • Education$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,236 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$108,457
Medicare patients
194
Services billed
1,694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$51,492
TrulicityDulaglutide32$46,604
EliquisApixaban35$45,601
XareltoRivaroxaban14$23,161
JardianceEmpagliflozin12$18,545
FarxigaDapagliflozin Propanediol37$18,332
Tresiba Flextouch U-100Insulin Degludec25$14,725
MounjaroTirzepatide13$13,348
LinzessLinaclotide15$7,781
NamzaricMemantine Hcl/Donepezil Hcl11$7,537
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$5,876
PaxlovidNirmatrelvir/Ritonavir19$4,159
Rosuvastatin Calcium270$3,918
SynthroidLevothyroxine Sodium36$3,156
Testosterone28$2,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$289$59,95245 claims
Novo NordiskOzempic$474$51,49242 claims
PfizerEliquis, Paxlovid, Levoxyl$193$50,48775 claims
Johnson & JohnsonXarelto$11$23,16114 claims
Boehringer IngelheimJardiance$19$18,54512 claims
AbbVieLinzess, Namzaric, Synthroid$262$18,47462 claims
AstraZenecaFarxiga$124$18,33237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →